首页> 外文OA文献 >Prolongation of tumour volume doubling time (midDT) is associated with improvement in disease-specific survival in patients with rapidly progressive radioactive iodine refractory differentiated thyroid cancer selected for molecular targeted therapy

【2h】

Prolongation of tumour volume doubling time (midDT) is associated with improvement in disease-specific survival in patients with rapidly progressive radioactive iodine refractory differentiated thyroid cancer selected for molecular targeted therapy

机译：肿瘤体积倍增时间（MIDDT）的延长与患者患者疾病特异性存活的改善有关，该患者为分子靶向治疗选择的迅速进行的放射性碘难治性分化甲状腺癌

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Mona M. Sabra; Eric Sherman; Robert Michael Tuttle;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类
入库时间 2022-08-20 22:04:33

相似文献

外文文献
中文文献
专利

1. Prolongation of tumour volume doubling time (midDT) is associated with improvement in disease‐specific survival in patients with rapidly progressive radioactive iodine refractory differentiated thyroid cancer selected for molecular targeted therapy [J] . Sabra Mona M., Sherman Eric, Tuttle Robert Michael Clinical Endocrinology . 2019,第4期

机译：肿瘤体积倍增时间（MIDDT）的延长与患者患者疾病特异性存活的改善有关，该患者为分子靶向治疗选择的迅速进行的放射性碘难治性分化甲状腺癌
2. Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease recurrence in properly selected patients with differentiated thyroid cancer [J] . F. Vaisman, A. Shaha, S. Fish, Clinical Endocrinology . 2011,第1期

机译：在适当选择的分化型甲状腺癌患者中，不进行放射性碘残留消融而采用甲状腺小叶切除术或全甲状腺切除术的初始治疗与极低的结构性疾病复发率相关
3. Tumor doubling time predicts response to sorafenib in radioactive iodine-refractory differentiated thyroid cancer [J] . Min Joo Kim, Seok-Mo Kim, Eun Kyung Lee, Endocrine journal . 2019,第7期

机译：肿瘤倍增时间预测放射性碘 - 难治分化甲状腺癌中索拉非尼的反应
4. MERAIODE: A Redifferentiation Phase II Trial With Trametinib and Dabrafenib Followed by Radioactive Iodine Administration for Metastatic Radioactive Iodine Refractory Differentiated Thyroid Cancer Patients With a BRAFV600E Mutation (NCT 03244956) [O] . Sophie Leboulleux, Christine Do Cao, Slimane Zerdoud, 2021

机译：Meraiode：用枪雷替尼和DabrafeNib进行重新化阶段II试验然后进行放射性碘施用转移性放射性碘难治性分化的甲状腺癌患者（NCT 03244956）
5. Structural Doubling Time Predicts Overall Survival in Patients with Medullary Thyroid Cancer in Patients with Rapidly Progressive Metastatic Medullary Thyroid Cancer Treated with Molecular Targeted Therapies [O] . Tiffany Yeh, Michele Yeung, Eric J. Sherman, 2020

机译：结构倍增时间预测患有分子靶向疗法迅速进行转移髓质甲状腺癌患者髓质甲状腺癌的患者的整体存活

Prolongation of tumour volume doubling time (midDT) is associated with improvement in disease-specific survival in patients with rapidly progressive radioactive iodine refractory differentiated thyroid cancer selected for molecular targeted therapy

著录项

相似文献

相关主题

期刊订阅